Navigation Links
Sirius Genomics Announces Issuance of U.S. Patent

Sirius Genomics Announces Issuance of U.S. Patent

Advanced Search Search

  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Medical Pharmaceuticals Click to view news release full screen  

Sirius Genomics Announces Issuance of U.S. Patent


VANCOUVER, Oct. 26 /PRNewswire/ - Sirius Genomics, a developer of companion diagnostics, announced today that U.S. Patent # 7,820,376 entitled "Protein C Polymorphisms" has been issued by the United States Patent and Trademark Office. The patent relates to a novel use of a Single Nucleotide Polymorphism (SNP) located in the Protein C gene.

"The patent covers methods of predicting outcome or prognosis in sepsis, and other related conditions, by determining a subject's genotype at the SNP. This patent issuance further strengthens Sirius' patent portfolio and position as a developer of companion diagnostics," stated Dr. Jennifer Kaufman-Shaw, Vice President, Intellectual Property at Sirius Genomics.

"Sirius Genomics' steadily expanding patent estate stems from discoveries made from the Company's focused approach in the identification and validation of genetic markers linked to drug response. Our focus is on improving outcomes for patients treated with various classes of drugs used in the acute care setting," stated Chris Wagner, President and CEO of Sirius Genomics.

Sirius' intellectual property portfolio includes patent families related to several therapies available and under development for sepsis and other acute conditions.  About Sirius Genomics:
Sirius Genomics develops companion diagnostics (CDx) that are closely tied to therapeutic decisions, leading to better patient outcomes through personalized medicine. Sirius generates value by improving the safety and effectiveness of pharmaceutical compounds. The Company correlates patient genetics with clinical outcomes, leading to proprietary and commercially viable CDx products that enable better drug treatment. The Company's first product is a genetic predictor of response to treatment for sepsis, a severe blood infection. Learn more at href="">

This release contains forward-looking statements that are not based on historical fact. These forward-looking statements involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on such forward-looking statements.

SOURCE Sirius Genomics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Sirius Genomics Announces New Collaboration with UK Critical Care Genomics Group
2. Sirius Genomics to Present at Invest Northwest Conference
3. Sirius Genomics Announces 2009 Board of Directors
4. Dr. Robert Lanza is Featured Guest on Deepak Chopras SIRIUS XM Stars Radio Show
5. Sirius Genomics Announces Change in Leadership
6. Learn Proven Practices to Measure, Align and Transform at SiriusDecisions Sales and Marketing Summit 2010
7. Industry Leaders from Blue Coat, Oracle, Polycom, Siemens and Taleo Headline SiriusDecisions Sales and Marketing Summit 2010
8. Sirius Genomics Announces Appointment of Senior Director of Business Development
9. Rosetta Genomics Announces Conference Call and Webcast of Second Quarter Financial Results
10. DOE JGI Director Eddy Rubin highlights the genomics of plant-based biofuels in the journal Nature
11. Rosetta Genomics Reports Second Quarter 2008 Financial Results
Post Your Comments:
(Date:12/1/2015)... Dec. 1, 2015  Symic, a clinical-stage biotherapeutics company ... matrix (ECM), today announced that it has secured $25 ... company,s pipeline, including its lead candidates SB-030 and SB-061. ... the participation by all existing major investors, as well ... total capital raised by Symic to over $43 million ...
(Date:12/1/2015)... December 1, 2015 ... the  "2016 U.K. Virology and Bacteriology Testing ... 100 Tests, Supplier Shares by Test, Innovative ... their offering.  --> ) ... U.K. Virology and Bacteriology Testing Market: Sales ...
(Date:11/30/2015)... radiology technique shows promise for helping morbidly obese patients lose ... presented today at the annual meeting of the Radiological Society ... --> --> Gastric artery embolization ... way to stop bleeding in emergency situations, but the idea ... is new. Mubin Syed , M.D., interventional radiologist ...
(Date:11/30/2015)... CALGARY , Nov. 30, 2015 /PRNewswire/ - Zenith Epigenetics ... appointed Dr. Norman C.W. Wong to its Board ... Wong comes to Zenith with a wealth of experience as ... and molecular biology. --> --> ... joining Zenith Epigenetics, board of directors. Zenith,s long standing expertise ...
Breaking Biology Technology:
(Date:11/19/2015)...  Although some 350 companies are actively involved in ... companies, according to Kalorama Information. These include Roche Diagnostics, Hologic, ... share of the 6.1 billion-dollar molecular testing market, according ... Molecular Diagnostic s .    ... by one company and only a handful of companies ...
(Date:11/17/2015)... -- Paris from 17 th ... Paris from 17 th until 19 th ... has invented the first combined scanner in the world which ... surface. Until now two different scanners were required: one for ... on the same surface. This innovation is an ideal ...
(Date:11/17/2015)... Nov. 17, 2015 Pressure BioSciences, Inc. (OTCQB: ... development and sale of broadly enabling, pressure cycling technology ... industry, today announced it has received gross proceeds of ... Private Placement (the "Offering"), increasing the total amount raised ... more additional closings are expected in the near future. ...
Breaking Biology News(10 mins):